PITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, ...

BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce ...

UPPSALA, SE / ACCESS Newswire / March 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Quarterly sales doubled, expanding market potential exponentiallySEK tQ3 24/25Q3 ...

A study published in November in the American Journal of Clinical Pathology that Emerson co-authored validated the analyzer against the Sysmex XN Automated Hematology System and found that CytoChip's ...

Operator: Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference ...

Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro ...

This was the only therapy available to humans for millennia, and we survived. Drug-based therapy, on the other hand, is what ...

We received -- we filed a dual submission, which was a 510(k) submission for both 510(k) and CLIA determination. After working extensively with the FDA, we determined and receiving feedback from ...

The ESPN documentary series "The Last Dance" showed a younger generation of NBA fans that Michael Jordan is much more than a guy who sells retro sneakers. For those who witnessed Jordan's ...

Key achievements included new customer acquisitions, successful FDA submissions for next-generation ... Laboratory Improvements Amendments (CLIA) - waiver dual submission pathway.

FDA requested additional information to supplement the application. Daxor elected to re-file this submission as a single 510(k) for a 90-day review pathway with the intention to file a separate CLIA ...